Injective Rallies as Trading Volume Rises, Staking Fund Proposed
Injective rose sharply on October 16, with sources reporting gains between 8% and 27% depending on timeframe and exchange. A proposed 21Shares fund would hold INJ directly and permit discretionary staking, drawing renewed institutional interest.
Written by CoinArticle’s AI Newsroom · from 2 cited sources. How we work
Price Movement and Volume Surge
Injective rallied on October 16, though sources differ on magnitude. Crypto.news reported an 8% gain to $9.35 on the day, citing TradingView data from Binance showing trading near $9.25. The Defiant reported a 27% surge over 24 hours, positioning INJ as the top performer among Layer 1 peers NEAR and Sei, as well as Cosmos Hub over the same period.
The discrepancy likely reflects different timeframes and exchange pairs; the broader move shows renewed buying pressure across multiple venues. Increased trading activity accompanied the price movement, signaling appetite from both retail and institutional traders resuming positions in the network.
Institutional Developments
A proposed 21Shares fund is driving part of the renewed interest, according to The Defiant. The fund would hold INJ directly and allow discretionary staking, a structure that could appeal to institutional investors seeking exposure without managing their own infrastructure. Crypto.news attributed the recovery partly to "renewed interest in the network's institutional developments", suggesting the fund announcement was the proximate catalyst.
No timeline for approval or launch was disclosed in either source.
Why It Matters
For Traders
The 24-hour volatility and volume surge suggest an intraday trading range; confirmation above $9.50 or a close below $8.50 would clarify whether the move has structural legs.
For Investors
A 21Shares fund with staking functionality could open INJ exposure to traditional fund platforms and wealth managers, expanding addressable market beyond self-custody holders.
For Builders
Institutional staking infrastructure normalizes Injective as infrastructure, potentially increasing long-term validator participation and network security assumptions.
This article is for information only and is not financial advice. Read the full disclaimer.
